{"id":5961,"date":"2017-10-11T13:45:48","date_gmt":"2017-10-11T13:45:48","guid":{"rendered":"https:\/\/oncopeptides.com\/about\/valberedning-2018\/"},"modified":"2026-03-06T10:13:18","modified_gmt":"2026-03-06T10:13:18","slug":"valberedning-2018","status":"publish","type":"about-us","link":"https:\/\/oncopeptides.com\/sv\/om-oss\/corporate-governance\/kommitteer\/valberedning-2018\/","title":{"rendered":"Valberedning 2018"},"content":{"rendered":"<p><strong>Enligt principerna f\u00f6r utseende av valberedning i Oncopeptides AB (publ), antagna vid \u00e5rsst\u00e4mman den 18 maj 2017, ska valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2018 best\u00e5 av ledam\u00f6ter utsedda av de tre r\u00f6stm\u00e4ssigt st\u00f6rsta aktie\u00e4garna per den 30 september, tillsammans med styrelsens ordf\u00f6rande.<\/strong><\/p>\n<p>Sammans\u00e4ttningen av valberedningen har nu fastst\u00e4llts, och Oncopeptides meddelade i dag att valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2018 best\u00e5r av f\u00f6ljande personer, som tillsammans representerar cirka 64,5 procent av antalet aktier och r\u00f6ster i bolaget baserat p\u00e5 den senast k\u00e4nda aktie\u00e4garinformationen per utg\u00e5ngen av september.<\/p>\n<ul>\n<li>Staffan Lindstrand, utsedd av HealthCap VI L.P.<\/li>\n<li>Nina Rawal, utsedd av Stiftelsen Industrifonden<\/li>\n<li>Max Mitteregger, utsedd av GLADIATOR<\/li>\n<li>Alan Hulme, styrelsens ordf\u00f6rande<\/li>\n<\/ul>\n<p>Valberedningens f\u00f6rslag kommer att presenteras i kallelsen till \u00e5rsst\u00e4mman 2018 och p\u00e5 Oncopeptides webbplats.<\/p>\n","protected":false},"featured_media":0,"parent":5990,"template":"","meta":{"_acf_changed":false},"protected-content":[],"class_list":["post-5961","about-us","type-about-us","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/about-us\/5961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/about-us"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/about-us"}],"version-history":[{"count":1,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/about-us\/5961\/revisions"}],"predecessor-version":[{"id":5994,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/about-us\/5961\/revisions\/5994"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/about-us\/5990"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=5961"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=5961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}